Researchers have identified enzymes in gut microorganisms that could cleave A and B antigens from red blood, transmuting them to O negative cells. This is “a decisive step forward” in the quest to develop a universal donor blood that can be administered to people of any blood group without eliciting a harmful immune response, according to Maher Abou Hachem of the Technical University of Denmark, who co-led the research. Read More
Researchers from the Beijing Institute of Radiation Medicine have presented the discovery of novel toll-like receptor (TLR)2/1 agonists as potential candidates for the treatment of lung cancer. Read More
Current approved antifungal therapies are limited by their associated adverse events. SCY-247 is a new triterpenoid antifungal for intravenous or oral administration that inhibits the glucan synthase enzyme, which is a key member for the fungal cell wall. Read More
Vedanta Biosciences Inc. has been awarded $3.9 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its VE-707 preclinical development program for reducing colonization and preventing subsequent infections caused by multidrug-resistant organisms (MRDOs). Read More
Tocris Cookson Ltd., Helmholtz Zentrum fur Infektionsforschung GmbH and University of Lübeck have described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands covalently bonded to non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) targeting moiety through linker reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Translational Genomics Research Institute has found macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer, osteoporosis and osteolysis. Read More
Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue. Read More
Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer. Read More
Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection. Read More
Novorex Inc. has patented protein ENL (MLLT1; YEATS1) and protein AF-9 (MLLT3; AF9) inhibitors reported to be useful for the treatment of cancer. Read More
Eluminex Biosciences Ltd. announced the FDA’s acceptance of their IND application for EB-105, a trispecific fusion antibody targeting vascular endothelial growth factor A (VEGF-A, and isomers), VEGF-B, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and interleukin-6 receptor (IL-6R) for the treatment of diabetic macular edema (DME). Read More
Debiopharm International SA has developed and presented a Fabl inhibitor, gofabicin, for the treatment of antibiotic-resistant Neisseria gonorrhoeae. Read More
